PMID- 21288628
OWN - NLM
STAT- MEDLINE
DCOM- 20110725
LR  - 20131121
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 155
IP  - 2
DP  - 2011 Apr
TI  - Treatment of moderate acne vulgaris using a combined oral contraceptive 
      containing ethinylestradiol 20 mug plus drospirenone 3mg administered in a 24/4 
      regimen: a pooled analysis.
PG  - 171-5
LID - 10.1016/j.ejogrb.2010.12.027 [doi]
AB  - OBJECTIVE: To investigate the effects of an ethinylestradiol (EE) 20 
      mug/drospirenone (drsp) 3mg combined oral contraceptive (COC) administered in a 
      24/4 regimen (24 active tablets/4 inert tablets per cycle) for the treatment of 
      moderate acne vulgaris, based on a pooled analysis of two identically designed US 
      studies. STUDY DESIGN: Healthy females (n=893) aged 14-45 years with moderate 
      facial acne were randomised to EE 20 mug/drsp 3mg COC (n=451) or placebo (n=442) 
      for six cycles. Primary outcome measures were mean percent change in acne lesion 
      counts and the investigators' assessment of acne from baseline to endpoint. 
      RESULTS: There were significantly greater reductions in the mean percent change 
      from baseline to endpoint in inflammatory, non-inflammatory and total lesion 
      counts in the EE 20 mug/drsp 3mg 24/4 COC group compared with the placebo group 
      (P<0.0001). The odds of women in the EE 20 mug/drsp 3mg 24/4 COC group having 
      'clear' or 'almost clear' skin as rated by the investigators at endpoint were 
      around three-fold greater than in the placebo group (odds ratio 3.41; 95% CI: 
      2.15-5.43; P<0.0001). CONCLUSIONS: A low-dose COC containing EE 20 mug/drsp 3mg 
      (24/4) more effectively reduced acne lesions than placebo and demonstrated 
      greater improvement in the investigator global assessment of acne.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Koltun, William
AU  - Koltun W
AD  - Medical Center for Clinical Research, San Diego, CA, USA.
FAU - Maloney, J Michael
AU  - Maloney JM
FAU - Marr, Joachim
AU  - Marr J
FAU - Kunz, Michael
AU  - Kunz M
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110202
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Androstenes)
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 0 (Estrogens)
RN  - 0 (Progestins)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - N295J34A25 (drospirenone)
SB  - IM
MH  - Acne Vulgaris/*drug therapy
MH  - Adolescent
MH  - Adult
MH  - Androstenes/administration & dosage/*therapeutic use
MH  - Contraceptives, Oral, Combined/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Estrogens/administration & dosage/therapeutic use
MH  - Ethinyl Estradiol/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Progestins/administration & dosage/therapeutic use
MH  - Severity of Illness Index
MH  - Young Adult
EDAT- 2011/02/04 06:00
MHDA- 2011/07/26 06:00
CRDT- 2011/02/04 06:00
PHST- 2010/03/19 00:00 [received]
PHST- 2010/12/07 00:00 [revised]
PHST- 2010/12/27 00:00 [accepted]
PHST- 2011/02/04 06:00 [entrez]
PHST- 2011/02/04 06:00 [pubmed]
PHST- 2011/07/26 06:00 [medline]
AID - S0301-2115(11)00008-X [pii]
AID - 10.1016/j.ejogrb.2010.12.027 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):171-5. doi: 
      10.1016/j.ejogrb.2010.12.027. Epub 2011 Feb 2.